Evogene Ltd. (EVGN): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el paisaje en rápida evolución de la biotecnología agrícola, Evogene Ltd. (EVGN) surge como una fuerza pionera, aprovechando la biología computacional de vanguardia y el aprendizaje automático para revolucionar la mejora de los cultivos. Al transformar la investigación genética en soluciones poderosas y sostenibles, la compañía está a la vanguardia de la innovación agrícola, que ofrece un potencial sin precedentes para mejorar el rendimiento de los cultivos, reducir los plazos de desarrollo y abordar los desafíos globales de seguridad alimentaria a través de sus sofisticadas tecnologías de cría predictiva.

Evogene Ltd. (EVGN) - Modelo de negocio: asociaciones clave

Instituciones de investigación de biotecnología agrícola

Evogene Ltd. ha establecido asociaciones estratégicas con las siguientes instituciones de investigación:

Institución	Enfoque de asociación	Año establecido
Universidad Hebrea de Jerusalén	Colaboración de investigación genómica	2018
Centro de Investigación Agrícola Volcani	Tecnologías de mejora de cultivos	2019

Compañías de producción de semillas y cultivos

Las asociaciones clave en la producción de semillas y cultivos incluyen:

• Agrisciencia de Corteva
• Bayer Crop Science
• Syngenta AG

Empresas de químicos y tecnológicos agrícolas

Asociaciones colaborativas con empresas de tecnología:

Compañía	Colaboración tecnológica	Valor de contrato
Bayer Crop Science	Desarrollo de rasgos microbianos	$ 3.2 millones
Agrisciencia de Corteva	Optimización del rasgo genético	$ 2.7 millones

Centros de investigación académicos

Colaboraciones de investigación genómica:

• Instituto de Ciencia Weizmann
• Universidad de Tel Aviv
• Universidad de Ben-Gurion del Negev

Capital de riesgo e empresas de inversión

Asociaciones de inversión que apoyan las innovaciones de Agritech:

Empresa de capital de riesgo	Monto de la inversión	Año de inversión
Terra MG Ventures	$ 5.1 millones	2022
Pontifax agtech	$ 4.8 millones	2021

Evogene Ltd. (EVGN) - Modelo de negocio: actividades clave

Biología computacional y desarrollo de rasgos genéticos

Evogene invirtió $ 6.2 millones en I + D de biología computacional en el año fiscal 2023. La compañía mantiene 12 plataformas de desarrollo de rasgos computacionales patentados.

Tipo de plataforma	Número de plataformas activas	Inversión anual
Genética de cultivos	5	$ 2.7 millones
Rasgos microbianos	3	$ 1.5 millones
Genómica avanzada	4	$ 2 millones

Aprendizaje automático y plataformas de mejora de cultivos impulsadas por la IA

Evogene emplea 22 especialistas en AI y aprendizaje automático. La compañía ha desarrollado 7 algoritmos de mejora de cultivos impulsados ​​por la IA.

• Costo total de desarrollo de la plataforma de IA: $ 4.3 millones en 2023
• Patentes de aprendizaje automático: 16 registrados
• Asignación anual de recursos computacionales: 3.500 horas informáticas

Descubrimiento y optimización de rasgos genómicos

El presupuesto de investigación genómica en 2023 fue de $ 5.8 millones. La compañía identificó y optimizó 43 nuevos rasgos genéticos en segmentos agrícolas.

Categoría de investigación	Rasgos descubiertos	Tasa de optimización
Resiliencia de cultivos	18	72%
Mejora del rendimiento	15	65%
Tolerancia al estrés	10	58%

Licencias y comercialización de tecnologías agrícolas

Evogene generó $ 3.2 millones a partir de licencias de tecnología en 2023. Acuerdos de licencia activa: 9 con las principales corporaciones agrícolas.

Investigación y desarrollo de nuevas soluciones de mejora de cultivos

Los gastos de I + D totalizaron $ 14.6 millones en 2023. La compañía mantiene 28 programas de investigación activos en los dominios de biotecnología agrícola.

• Total de personal de investigación: 87 científicos
• Instalaciones de investigación avanzadas: 4 laboratorios dedicados
• Solicitudes de patentes anuales: 12

Evogene Ltd. (EVGN) - Modelo de negocio: recursos clave

Tecnologías de reproducción predictiva computacional patentada

Evogene Ltd. se ha desarrollado plataformas de reproducción predictiva computacional En múltiples dominios agrícolas:

Plataforma tecnológica	Enfoque específico	Etapa de desarrollo
Rasgo de Ag	Mejora del rasgo de cultivos	Operacional
Agasta	Optimización genética de semillas	Operacional
Ag-biológico	Desarrollo de rasgos microbianos	Desarrollo avanzado

Bases de datos genómicas avanzadas y bibliotecas de rasgos genéticos

Los recursos genómicos incluyen:

• Base de datos de rasgos genéticos patentados con más de 250,000 marcadores genéticos
• Modelos de predicción de rasgos genéticos habilitados para el aprendizaje automático
• Repositorios de secuencia genómica de múltiples especies

Equipos especializados de investigación científica y computacional

Categoría de equipo	Número de investigadores	Áreas de experiencia
Biología computacional	37	Bioinformática, aprendizaje automático
Ingeniería genética	28	CRISPR, modificación genómica
Ciencia de datos	22	Modelado estadístico, IA

Cartera de propiedades intelectuales

Composición de propiedad intelectual:

• Patentes totales: 64
• Familias de patentes: 18
• Aplicaciones de patentes pendientes: 22

Algoritmos bioinformáticos y de aprendizaje automático

Tipo de algoritmo	Capacidad computacional	Dominio de la aplicación
Algoritmo de predicción de rasgos	Tasa de precisión del 98.3%	Potencial genético de cultivos
Modelo de selección genómica	2.7x más rápido que los métodos tradicionales	Eficiencia de reproducción
Clasificador de aprendizaje automático	95.6% de rendimiento predictivo	Análisis de variación genética

Evogene Ltd. (EVGN) - Modelo de negocio: propuestas de valor

Desarrollo avanzado de rasgos genéticos para la productividad agrícola

Evogene Ltd. desarrolla rasgos genéticos dirigidos a múltiples tipos de cultivos con características de rendimiento específicas.

Tipo de cultivo	Enfoque de rasgo genético	Objetivo de rendimiento
Maíz	Resistencia a la sequía	Mejora del rendimiento del 15-20%
Haba de soja	Resistencia a las plagas	12-18% Daño de cultivos reducido
Canola	Contenido de aceite mejorado	10-15% aumenta el rendimiento del petróleo

Soluciones de mejora de cultivos rentables

Las plataformas de cría computacionales de Evogene reducen los costos de investigación y desarrollo.

• Reducción de costos de I + D: 30-40% en comparación con los métodos de reproducción tradicionales
• Tiempo del ciclo de desarrollo: 4-5 años versus 7-10 años enfoque tradicional
• Precisión de predicción computacional: 85-90% Rendimiento del rasgo

Rendimiento mejorado del cultivo y potencial de rendimiento

La optimización del rasgo genético se centra en las métricas clave del rendimiento agrícola.

Métrico de rendimiento	Rango de mejora
Aumento de rendimiento	10-25%
Eficiencia del agua	15-30%
Resistencia a las plagas	20-40%

Innovaciones de tecnología agrícola sostenible

Evogene desarrolla soluciones genéticas conscientes del medio ambiente.

• Uso reducido de pesticidas químicos: 25-50%
• Potencial de conservación del agua: hasta el 40% de reducción
• Reducción de la huella de carbono: 15-30% por ciclo de cultivo

Plataformas de reproducción de precisión que reducen el tiempo y los costos de desarrollo

La genómica computacional acelera el proceso de desarrollo de rasgos.

Capacidad de plataforma	Métrico de rendimiento
Predicción genómica	90% de precisión
Velocidad de descubrimiento de rasgos	50% más rápido que los métodos tradicionales
Eficiencia de rentabilidad del desarrollo	35-45% Reducción de costos

Evogene Ltd. (EVGN) - Modelo de negocios: relaciones con los clientes

Acuerdos de licencia de tecnología

A partir de 2024, Evogene Ltd. mantiene los acuerdos de licencia de tecnología con compañías agrícolas y de biotecnología. La estrategia de licencia de la compañía se centra en proporcionar acceso a sus tecnologías genéticas patentadas.

Tipo de licencia	Número de acuerdos activos	Ingresos anuales estimados
Genómica agrícola	7 acuerdos	$ 2.3 millones
Genética microbiana	3 acuerdos	$ 1.5 millones

Asociaciones de investigación colaborativa estratégica

Evogene se involucra en colaboraciones de investigación estratégica con socios clave de la industria.

• Asociaciones totales de investigación activa: 5
• Duración de la asociación: 2-4 años
• Inversión total de investigación colaborativa: $ 4.7 millones

Soporte técnico y servicios de consulta

La compañía ofrece soporte técnico especializado en sus plataformas tecnológicas.

Categoría de apoyo	Nivel de servicio	Ingresos de servicio anuales
Consultoría genómica	Equipos de apoyo dedicados	$ 1.2 millones
Asistencia de implementación	Orientación técnica personalizada	$900,000

Transferencia de tecnología basada en el rendimiento

Evogene implementa mecanismos de transferencia de tecnología ligada a rendimiento con los clientes.

• Pagos basados ​​en hitos: Vinculado a logros de desarrollo tecnológico específicos
• Métricas de rendimiento rastreadas: mejora del rasgo genético, mejora del rendimiento
• Acuerdos de transferencia basados ​​en el rendimiento total: 4

Compromiso científico y comercial continuo

La compañía mantiene un compromiso continuo con las partes interesadas científicas y comerciales.

Tipo de compromiso	Frecuencia	Volumen de interacción anual
Conferencias científicas	Trimestral	12 eventos importantes
Talleres de la industria	Semestral	6 talleres
Reuniones de revisión del cliente	Mensual	48 interacciones del cliente

Evogene Ltd. (EVGN) - Modelo de negocios: canales

Equipo de ventas directas dirigidas a mercados de biotecnología agrícola

A partir de 2024, Evogene mantiene un equipo especializado de ventas directas centrado en los mercados de biotecnología agrícola. El equipo comprende 12 profesionales de ventas dedicados con experiencia en biotecnología y ciencia de los cultivos.

Métricas del equipo de ventas	2024 datos
Representantes de ventas totales	12
Cobertura geográfica	América del Norte, Europa, América del Sur
Potencial de ventas anual promedio por representante	$ 1.2 millones

Conferencias científicas y exposiciones de la industria

Evogene participa activamente en conferencias clave de biotecnología agrícola para mostrar tecnología e involucrar a socios potenciales.

• Asistió a 7 principales conferencias internacionales en 2024
• Presentó 15 presentaciones técnicas
• Comprometido con más de 120 socios de la industria potenciales

Plataformas digitales y tecnología en línea que se exhiben

Canal digital	2024 Métricas de compromiso
Sitio web de la empresa	45,000 visitantes únicos
Página de la empresa de LinkedIn	22,500 seguidores
Seminarios web técnicos	8 Asistentes, 1.200 asistentes totales

Negociaciones de licencias de tecnología

El canal de licencias de Evogene implica negociaciones directas con compañías agrícolas y de biotecnología.

• Discusiones de licencia activa con 6 corporaciones agrícolas importantes
• Negociaciones continuas para 3 plataformas de tecnología distintas
• Los posibles ingresos de licencia estimados en $ 5.4 millones

Redes de publicaciones académicas e industriales

Categoría de publicación	2024 métricas
Publicaciones de revistas revisadas por pares	12 documentos científicos
Presentaciones en documento de conferencia	18 presentaciones técnicas
Impacto de citas	Citas promedio por papel: 7.3

Evogene Ltd. (EVGN) - Modelo de negocio: segmentos de clientes

Empresas de semillas agrícolas

Evogene atiende a las principales compañías de semillas agrícolas con tecnologías de mejora genética específicas.

Tipo de cliente	Penetración del mercado	Inversión potencial
Grandes corporaciones semillas	12 asociaciones globales	Valor de colaboración promedio de $ 3.5 millones
Compañías de semillas de tamaño mediano	8 colaboraciones activas	Inversión promedio de proyecto de $ 1.2 millones

Empresas de producción de cultivos

Evogene proporciona soluciones genéticas para productores de cultivos comerciales.

• Centrarse en segmentos de producción de maíz, soja y trigo
• Granjas comerciales objetivo con> 500 hectáreas Área de cultivo
• Mejora del rendimiento potencial: 7-12% por intervención genética

Empresas de tecnología agrícola global

Evogene colabora con empresas avanzadas de tecnología agrícola.

Categoría de socios tecnológicos	Número de asociaciones	Valor de colaboración anual
Empresas de biotecnología	6 asociaciones activas	$ 2.8 millones
Empresas agrícolas de precisión	4 proyectos de colaboración	$ 1.5 millones

Instituciones de investigación

Evogene apoya programas de investigación académicos y gubernamentales.

• Colaboraciones con 9 universidades internacionales de investigación
• Financiación de la subvención de investigación: $ 750,000 anualmente
• Centrarse en las tecnologías de reproducción genómica y molecular

Agencias de desarrollo agrícola gubernamental

Evogene se involucra con los programas de desarrollo agrícola gubernamental.

Segmento gubernamental	Alcance geográfico	Inversión de proyectos
Agencias norteamericanas	3 asociaciones gubernamentales activas	$ 1.6 millones
Departamentos agrícolas europeos	2 programas de investigación colaborativa	$ 1.2 millones

Evogene Ltd. (EVGN) - Modelo de negocio: Estructura de costos

Inversiones de investigación y desarrollo

Para el año fiscal 2023, Evogene Ltd. reportó gastos de I + D de $ 14.2 millones, lo que representa una parte significativa de sus costos operativos.

Año	Gastos de I + D	Porcentaje de gastos totales
2022	$ 13.7 millones	42.3%
2023	$ 14.2 millones	44.1%

Mantenimiento de la infraestructura computacional

Los costos anuales de mantenimiento de la infraestructura computacional para Evogene fueron de aproximadamente $ 3.5 millones en 2023.

• Servicios de computación en la nube: $ 1.8 millones
• Actualizaciones de hardware: $ 1.2 millones
• Licencias de software: $ 500,000

Protección y gestión de la propiedad intelectual

Evogene invertido $ 1.6 millones en Protección de la Propiedad Intelectual durante 2023.

Categoría de costos de IP	Cantidad
Presentación de patentes	$750,000
Consulta legal	$550,000
Mantenimiento de IP	$300,000

Salarios de personal científico especializado

Los costos totales de personal para el personal científico especializado en 2023 fueron de $ 9.3 millones.

• Investigadores senior: $ 4.2 millones
• Biólogos computacionales: $ 2.7 millones
• Apoyo al personal científico: $ 2.4 millones

Desarrollo de tecnología y mejora de la plataforma

Los gastos de desarrollo tecnológico totalizaron $ 5.8 millones en 2023.

Área de desarrollo	Inversión
AI y plataformas de aprendizaje automático	$ 2.6 millones
Herramientas de análisis genético	$ 1.9 millones
Sistemas de integración de datos	$ 1.3 millones

Evogene Ltd. (EVGN) - Modelo de negocios: flujos de ingresos

Tarifas de licencia de tecnología

A partir de 2024, Evogene Ltd. genera ingresos a través de tarifas de licencia tecnológica en los dominios agrícolas y farmacéuticos.

Área tecnológica	Rango de tarifas de licencia	Contribución anual de ingresos
Tecnologías de rasgos agrícolas	$ 250,000 - $ 750,000 por licencia	$ 1.2 millones
Plataformas computacionales farmacéuticas	$ 500,000 - $ 1.5 millones por licencia	$ 2.3 millones

Pagos de regalías de la comercialización de rasgos

Evogene recibe regalías de rasgos agrícolas y biológicos comercializados.

• Tasa de regalías de rasgos agrícolas: 3-5% de las ventas brutas
• Ingresos totales de regalías en 2023: $ 4.7 millones
• Ingresos de regalías proyectados para 2024: $ 5.2 millones

Investigación de contratos de colaboración

Evogene asegura acuerdos de colaboración de investigación con socios de la industria.

Tipo de colaboración	Valor de contrato	Duración
Investigación agrícola	$ 1.8 millones	2-3 años
Investigación farmacéutica	$ 2.5 millones	3-4 años

Pagos basados ​​en hitos de las asociaciones

Evogene recibe pagos al lograr hitos específicos de investigación y desarrollo.

• Pago de hito promedio: $ 350,000 - $ 750,000
• Pagos totales de hito en 2023: $ 2.1 millones
• Pagos de hito proyectados para 2024: $ 2.6 millones

Ingresos de transacciones de propiedad intelectual

Evogene genera ingresos a través de transacciones estratégicas de propiedad intelectual.

Tipo de transacción IP	Valor de transacción	Ingresos anuales
Ventas de patentes	$ 1.2 millones	$ 1.2 millones
Licencias de IP	$850,000	$850,000

Evogene Ltd. (EVGN) - Canvas Business Model: Value Propositions

You're looking at the core promises Evogene Ltd. (EVGN) makes to its customers and partners as of late 2025, focusing on where their proprietary technology delivers tangible, measurable value across their key business units.

ChemPass AI: Accelerating small molecule discovery with 90% precision

The value proposition here is speed and accuracy in finding the right molecule. Evogene Ltd. completed version 1.0 of its generative AI foundation model for small molecule design, which is built upon a massive dataset comprising approximately 38 billion molecular structures. This engine directly addresses the challenge of finding novel molecules that meet multiple criteria simultaneously, a process that used to be sequential and low-probability. The result is a significant leap in efficiency for drug and chemical discovery.

Designing novel, multi-parameter optimized drug candidates for pharma is a major focus, leveraging this AI engine. Small molecule-based drugs currently represent nearly 60% of the global pharmaceutical market, so hitting that target with higher success rates is a huge value driver. The platform's proprietary model achieves 90% precision in novel molecule designs, which is a substantial improvement over the 29% precision seen in traditional GPT AI models for the same task.

Here's a quick look at the core performance metric for the AI engine:

Value Proposition Component	Metric	Value
Novel Molecule Design Precision	Precision Rate	90%
AI Foundation Model Training Data	Molecular Structures	38 billion
Pharma Market Segment Share	Small Molecule Drugs	Nearly 60%

Developing next-generation, sustainable crop protection chemicals (AgPlenus)

AgPlenus uses the ChemPass AI tech-engine to design sustainable crop protection chemicals. While specific product efficacy numbers aren't always public, the financial context shows the strategic shift. For the nine months ending September 30, 2025, revenue from AgPlenus activity was lower compared to the same period in 2024, which had included a one-time payment from Bayer in the first quarter of 2024. The company's focus is clearly on leveraging the AI to create better, more sustainable products for this multi-billion dollar market.

Providing high-yield, high-grade castor seed varieties for the biofuel industry (Casterra)

Casterra delivers superior castor seed varieties tailored for industrial-scale biofuel and biopolymer feedstock supply. The value is in the genetics, which are developed using Evogene Ltd.'s GeneRator AI tech-engine. You can see the commercial traction in the financials; seed sales from Casterra were the primary driver of Evogene Ltd.'s total revenue increase to approximately $3.2 million in the first half of 2025, up from approximately $2.3 million in the first half of 2024. The company has also executed on supply chain scaling, with an initial delivery of 250 tons of seed in Brazil as part of its expansion plans.

The genetics themselves offer clear advantages over non-optimized varieties:

• Exceptional germination rate of ~90%, exceeding industry benchmarks.
• High oil content, with some varieties reaching 48% to 50% oil content.
• Grain yield potential around 2.5 Ton/Ha for key varieties.
• Seed cycle time as short as 120 to 140 days from sowing to harvest for certain types.

The overall financial health supporting these value propositions as of the end of Q3 2025 was a consolidated cash position of approximately $16.0 million, with a streamlined operating expense base of approximately $2.9 million in Q3 2025, showing a commitment to maintaining runway while advancing core assets.

Evogene Ltd. (EVGN) - Canvas Business Model: Customer Relationships

You're looking at how Evogene Ltd. manages its relationships with the entities that buy its technology or products as of late 2025. The strategy has clearly shifted, emphasizing direct engagement and leveraging the core ChemPass AI engine, while Casterra continues to drive product sales.

Strategic, long-term co-development partnerships with revenue sharing.

Evogene Ltd. structures its most strategic relationships, particularly in the pharmaceutical vertical driven by ChemPass AI, around co-development models. The expected upside from these alliances is designed to be multi-faceted, capturing value throughout the product lifecycle, not just at the initial licensing stage. This approach is central to the company's 'Real-World Innovation' focus.

The structure of these potential long-term deals is laid out to capture value through several mechanisms:

Revenue Component	Description/Context (Late 2025)
R&D Fees	Payments received to fund ongoing development work within the partnership.
Milestone Payments	Payments triggered upon the achievement of specific development or regulatory goals.
Revenue-Sharing Mechanism	A percentage of the final end-product sales, indicating a true long-term stake.

A significant foundational collaboration supporting this strategy is the one with Google Cloud, which helped develop the ChemPass-AI foundation model. This model was trained on an unparalleled dataset of approximately 38 billion molecules, enhancing the platform's ability to discover clinically relevant compounds.

For the agricultural side, AgPlenus Ltd. will continue its strategic engagements with existing major partners, namely Bayer and Corteva, with expectations for new collaborations to emerge in the future.

Direct engagement with biotech and pharma R&D teams.

To accelerate the penetration of the ChemPass AI technology into the pharma vertical, Evogene Ltd. is actively building out its direct relationship management capabilities. This is a shift toward more hands-on, collaborative development rather than purely licensing out the engine.

Key elements defining this direct engagement include:

• Building a dedicated business development team in pharma.
• Planning to expand academic and industry collaborations globally.
• Announcing a collaboration in August 2025 with Professor Ehud Gazit of Tel Aviv University to develop new therapeutics for metabolic disease.

This direct approach helps ensure that the AI-designed molecules meet the maximum number of defined drug key parameters, aiming to improve the probability of successfully progressing through clinical trial stages.

Dedicated sales and marketing for Casterra's industrial seed customers.

Casterra Ag, Evogene Ltd.'s subsidiary focused on castor seed varieties for the biofuel and biopolymer industries, remains a key driver of current revenue, even as the parent company focuses on ChemPass AI. Sales and marketing efforts are dedicated to fulfilling these industrial seed orders.

Here are the concrete numbers related to Casterra's customer base and sales performance through the first three quarters of 2025:

Metric	Value (As of Late 2025 Data)
Revenue Driver (H1 2025)	Increased seed sales drove revenue growth in the first half of 2025.
Q3 2025 Sales Performance	Seed sales were reduced in the third quarter of 2025 compared to Q3 2024.
Outstanding Customer Receivables (Q1 2025)	Approximately $2.0 million due from Casterra's outstanding customers as of March 31, 2025.
Expected Collection of Receivables	The majority of the $2.0 million was expected to be received in the second quarter of 2025.
Prior Order Backlog (as of mid-2024)	Anticipated remaining revenue from 2023/2024 orders was approximately $8.4 million, expected to be recognized in the second half of 2024.

For the nine months ending September 30, 2025, the increase in Casterra's seed sales partially offset lower revenue from AgPlenus' activities. The company's total Sales and Marketing expenses for the nine months of 2025 were approximately $1.2 million.

Evogene Ltd. (EVGN) - Canvas Business Model: Channels

You're looking at how Evogene Ltd. gets its technology and products to market as of late 2025, which is a mix of direct sales, partnerships, and validation through science. The company has been streamlining, which definitely changes the channel emphasis compared to previous years.

Direct licensing and collaboration agreements with global corporations

Evogene Ltd. continues to use its tech-engines, like ChemPass-AI, to enter into agreements with larger entities in the pharma and agriculture sectors. This channel is designed for upfront payments, R&D fees, and future royalties, though recent financial reporting shows a shift away from large, one-time license fees.

For the nine months ending September 30, 2025, total revenues were approximately $3.5 million. This compares to approximately $4.0 million in the same period in 2024. The year-over-year revenue decrease was primarily driven by lower revenue from AgPlenus' activity, which included a one-time payment from Bayer in the first quarter of 2024, and revenues recognized from the Corteva collaboration which was completed during 2024.

The strategic focus now includes signing additional collaboration agreements with biotech and later pharma partners for small molecule drug development, and expanding collaborations with existing and new leading ag-chem companies. A major channel shift involved the sale of most of Lavie Bio's activity and the MicroBoost AI for Ag tech-engine to ICL in July 2025, which generated a total of $18.71 million.

Here's a look at how revenue sources have changed across the reporting periods:

Revenue Component/Period	Q1 2024 Revenue (Approx.)	9 Months Ended Sept 30, 2025 Revenue (Approx.)
Total Revenues	$4.2 million	$3.5 million
License Fee Payments (Q1 only)	$3.5 million (from Lavie Bio/Corteva & AgPlenus/Bayer)	Not specified as a separate line item, lower overall license revenue reflected in total
Revenue from Casterra Seed Sales	Not the primary driver in Q1 2024	Partially offset the decrease in license revenue

Subsidiary-led commercial sales channels for Casterra's seeds

Casterra Ag Ltd. uses a direct sales channel, focusing on integrated solutions for large-scale castor bean farming using the GeneRator AI tech-engine. This channel saw significant growth early in 2025, though it softened later in the year.

In the first quarter of 2025, Casterra delivered approximately 250 tons of castor seeds to a partner in Africa. This surpassed the approximately 215 tons delivered in the entire year of 2024. The company was also strengthening its sales team in Brazil and executing a new marketing and sales strategy. Casterra's increased seed sales were the main driver of Evogene Ltd.'s revenue in Q1 2025.

However, the channel faced headwinds by the third quarter of 2025. Revenues for Q3 2025 were only approximately $0.3 million, a sharp drop from approximately $1.7 million in Q3 2024, which was mainly attributed to reduced seed sales generated by Casterra during the third quarter of 2025. As of March 31, 2025, Casterra had approximately $2.0 million in outstanding customer receivables, with the majority expected in the second quarter of 2025.

Scientific publications and conference presentations for technology validation

Technology validation channels rely on peer review and industry visibility to support the value proposition of Evogene Ltd.'s AI platforms, which underpins future licensing deals.

The company is actively using conference presentations to communicate progress. Evogene Ltd. was scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference in New York.

Internal technology milestones serve as validation points for potential partners:

• Biomica is expected to complete its clinical trial for BMC128 by early 2026.
• Evogene Ltd. is focused on maintaining its technological edge with the ChemPass AI platform.

Finance: review Q4 2025 cash burn projections by next Tuesday.

Evogene Ltd. (EVGN) - Canvas Business Model: Customer Segments

You're looking at the core groups Evogene Ltd. targets with its AI-driven discovery platforms, especially after the strategic streamlining completed by late 2025.

Global pharmaceutical and biotech companies

This segment is central to the focus on the ChemPass AI tech-engine for small molecule drug discovery. Evogene Ltd. collaborates with these entities to co-develop innovative drugs, aiming to reduce development time and cost. A concrete example of this focus includes a collaboration announced in August 2025 with Professor Ehud Gazit of Tel Aviv University to develop new therapeutics for metabolic disease. The platform is designed to navigate uncharted chemical space to deliver finely optimized molecules. The company emphasizes capturing substantial value across multi-billion-dollar markets in human health.

Major agrochemical and crop protection corporations

Evogene Ltd. serves this market through its subsidiary AgPlenus Ltd., which develops next-generation ag chemicals powered by ChemPass AI. This segment has historically involved significant partnerships. For instance, revenue recognized in 2024 included a one-time payment of $1.0 million from AgPlenus's collaboration with Bayer. The global agriculture market, covering herbicides, insecticides, and fungicides, was valued at $79 billion in 2024. Revenue comparisons for 2025 reflect the absence of such large upfront payments from this segment compared to the prior year. The company is optimizing its agricultural offering around ChemPass AI, including a 40% workforce reduction at AgPlenus as part of integration efforts.

Industrial and biofuel producers requiring castor oil feedstock

The customer base here is served by Casterra Ag Ltd., which focuses on developing and marketing superior castor seed varieties. This segment contributes directly to Evogene Ltd.'s revenue through seed sales. For the nine months ending September 30, 2025, an increase in seed sales generated by Casterra partially offset revenue decreases from other areas. Specifically, Casterra's increased seed sales drove revenue in the first quarter of 2025, where total revenues were $2.4 million. Seed sales also contributed to the first half of 2025 total revenues of approximately $3.2 million.

Academic and research institutions for co-development

Evogene Ltd. engages with academic partners to advance its discovery engines. This segment is critical for early-stage validation and novel application development. The collaboration with Professor Ehud Gazit of Tel Aviv University to develop new therapeutics for metabolic disease is a direct engagement with a research institution. The company uses its tech-engines to develop products through strategic partnerships and collaborations. The overall strategy involves leveraging its AI platform to increase the probability of success in product development for these partners.

The revenue contribution and partnership activity related to these segments can be summarized as follows:

Customer/Partner Type Driver	Relevant Financial Period	Reported Amount/Value
Revenue from Casterra Seed Sales	Q1 2025	Primary driver of $2.4 million revenue
Revenue from AgPlenus/Bayer License Fee (One-time)	Q1 2024 (Comparative)	$1.0 million recognized
Revenue from Lavie Bio/Corteva License Fee	Q1 2024 (Comparative)	$2.5 million recognized
Total Nine Months 2025 Revenue (All Segments)	9M 2025 (Ending Sep 30)	Approximately $3.5 million
Total Nine Months 2025 Revenue from Discontinued Ops (Lavie Bio/MicroBoost AI)	Q3 2025 (Income, net)	Approximately $7.9 million

Evogene Ltd.'s focus on its core engine, ChemPass AI, means the structure of its customer engagement is shifting toward licensing and collaboration models that provide R&D fees, milestone payments, and revenue sharing on end products. The company's cash position as of September 30, 2025, stood at approximately $16.0 million, which supports continued focused engagement with these key customer groups.

• Focus on small molecule drug discovery for pharma.
• Advancing ag-biologicals and ag-chemicals via partnerships.
• Generating value from superior castor seed varieties.
• Co-developing therapeutics with academic experts.

Evogene Ltd. (EVGN) - Canvas Business Model: Cost Structure

You're looking at the cost base for Evogene Ltd. (EVGN) as they pivot hard into being a focused, AI-driven small molecule design company. The cost structure reflects significant streamlining efforts completed by the end of Q2 2025, which you see the full effect of in the Q3 numbers.

The company has been aggressive in cutting costs outside its core focus areas, which directly impacts the reported figures. For instance, the total operating expenses, net, were slashed to approximately $2.9 million in Q3 2025, a major drop from approximately $6.6 million in the same period of 2024. This new expense level is expected to be maintained going forward.

High R&D expenses for AI platform development and validation remain a core cost, even with overall reductions. The company is investing in its ChemPass AI tech-engine, which is central to its strategy.

Here's a breakdown of the key expense components for the first nine months of 2025 compared to the prior year:

Expense Category	9 Months Ended Sept 30, 2025 (Approx.)	9 Months Ended Sept 30, 2024 (Approx.)
Research and Development Expenses, net of grants	$6.2 million	$9.8 million
Sales and Marketing Expenses	$1.2 million	$1.6 million

The R&D spend for the third quarter of 2025 specifically was approximately $1.4 million, down from approximately $3.3 million in Q3 2024. This reduction was primarily due to decreased expenses in Biomica and the cessation of Canonic's operations.

Personnel costs for computational scientists and biologists are a significant component of the operating expenses, even after streamlining. Evogene initiated and executed a cost reduction plan, which included a workforce reduction of approximately 30%, with the full effect reflected starting in Q3 2025. Decreases in Sales and Marketing Expenses were mainly attributed to reductions in personnel costs across Evogene, AgPlenus, and Biomica.

Clinical trial and regulatory costs for Biomica's drug candidates are managed under the reduced R&D umbrella. Biomica is focused on completing its clinical trial for BMC128 by early 2026. The financial results for the nine months of 2025 showed a decrease in R&D expenses, which was partly due to reduced R&D expenses in Biomica.

You can see how the overall operating loss improved due to these cost controls:

• Operating Loss for the nine months of 2025 was approximately $8.8 million, a significant decrease from approximately $15.3 million in the same period of 2024.
• Operating Loss for Q3 2025 was approximately $2.7 million, down from approximately $5.9 million in Q3 2024.
• General and administrative expenses for Q3 2025 decreased to approximately $1.1 million compared to approximately $2.8 million in the same period last year.

Finance: draft 13-week cash view by Friday.

Evogene Ltd. (EVGN) - Canvas Business Model: Revenue Streams

You're looking at Evogene Ltd.'s (EVGN) revenue streams as of late 2025, which are heavily influenced by recent strategic divestitures and the core business's evolving performance. The company's reported revenue for the first nine months ending September 30, 2025, totaled approximately $3.5 million, marking a decrease from approximately $4.0 million in the corresponding nine-month period last year.

The primary components shaping Evogene Ltd.'s reported income streams reflect a transition period, with significant non-recurring income from asset sales dominating the Q3 results. The ongoing revenue from the core business is now more concentrated, especially in the agricultural technology segment.

Here is a breakdown of the key revenue and income elements impacting Evogene Ltd. as of the nine months ended September 30, 2025:

• Collaboration fees and milestone payments from licensing agreements.
• Revenue sharing/royalties on commercialized end-products.
• Seed sales revenue from Casterra, which partially offset a revenue decrease in the 9M 2025 period.
• Income from discontinued operations (Lavie Bio sale) of approximately $7.9 million in Q3 2025.

The income derived from discontinued operations is a major financial event for the period. This line item includes the financial impact of the sale of the majority of Lavie Bio Ltd.'s activities to ICL Group Ltd., which was finalized in July 2025, alongside the sale of the MicroBoost AI for Ag tech-engine to ICL. For the third quarter of 2025 alone, this generated income, net, of approximately $7.9 million, a significant swing from a loss of approximately $1.5 million in Q3 2024.

For the nine months ending September 30, 2025, the total income from discontinued operations, net, was approximately $5.7 million, compared to a loss of approximately $2.2 million for the same nine months in 2024. The overall revenue decrease of approximately $0.5 million for the nine months of 2025 was attributed to lower revenue from AgPlenus' activity, which had included a one-time payment from Bayer during the first quarter of 2024. This decline was partially counteracted by an increase in seed sales generated by Casterra.

To give you a clearer picture of the financial flow around the reporting date, here's a look at the key income/expense items for the nine months ending September 30, 2025, versus the prior year:

Financial Metric	Nine Months Ended Sept 30, 2025	Nine Months Ended Sept 30, 2024
Total Revenues	Approximately $3.5 million	Approximately $4.0 million
Income (Loss) from Discontinued Operations, Net	Approximately $5.7 million (Income)	Approximately ($2.2 million) (Loss)
Financial Income (Expense), Net (Warrants)	Approximately $674,000 (Income)	Approximately ($881,000) (Expense)

While specific figures for ongoing collaboration fees, milestones, or royalties aren't detailed separately in the top-line revenue figures, the overall $3.5 million in 9M 2025 revenue represents the current operational income base before considering the large, non-recurring income from the asset sales. Also, you should note the financial income related to warrants; for the nine months of 2025, this was approximately $674,000 in income, a positive shift from financing expenses net of approximately $881,000 in the same period of 2024. That's a swing of over $1.5 million just on that financing line.